{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:14:22Z","timestamp":1790712862458,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.esmoop.2026.107697","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:31:26Z","timestamp":1778761886000},"page":"107697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and\/or metastatic solid tumors"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3865-4574","authenticated-orcid":false,"given":"U.","family":"Lassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.J.","family":"van Brummelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6249-7209","authenticated-orcid":false,"given":"E.","family":"Angevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0281-2507","authenticated-orcid":false,"given":"H.","family":"Joensuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3047-2303","authenticated-orcid":false,"given":"N.H.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mau-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-2279","authenticated-orcid":false,"given":"N.","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Rodr\u00edguez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0912-6198","authenticated-orcid":false,"given":"K.","family":"Homicsko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ca\u00f1amero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dejardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5806-7650","authenticated-orcid":false,"given":"C.","family":"Habigt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Guarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8608-4457","authenticated-orcid":false,"given":"G.","family":"Babitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4928-6284","authenticated-orcid":false,"given":"H.E.S.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7801-9121","authenticated-orcid":false,"given":"C.","family":"Adessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Boetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3060-9429","authenticated-orcid":false,"given":"S.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Charo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Teichgr\u00e4ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1487-7108","authenticated-orcid":false,"given":"G.","family":"Argil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.107697_bib1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2026.107697_bib2","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.107697_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.107697_bib4","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/ni1105-1071","article-title":"Fueling regulation: IL-2 keeps CD4+ Treg cells fit","volume":"6","author":"Maloy","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.esmoop.2026.107697_bib5","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107697_bib6","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107697_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0022-5347(17)40872-X","article-title":"Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy","volume":"141","author":"Belldegrun","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.esmoop.2026.107697_bib8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.1989.7.4.486","article-title":"Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines","volume":"7","author":"Margolin","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107697_bib9","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni1263","article-title":"A function for interleukin 2 in Foxp3-expressing regulatory T cells","volume":"6","author":"Fontenot","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.esmoop.2026.107697_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/path.2803","article-title":"Jekyll and Hyde: the role of the microenvironment on the progression of cancer","volume":"223","author":"Allen","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.esmoop.2026.107697_bib11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/1744666X.2014.875856","article-title":"Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy","volume":"10","author":"Skrombolas","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.esmoop.2026.107697_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1163462","article-title":"Role of IL-2 in cancer immunotherapy","volume":"5","author":"Jiang","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.esmoop.2026.107697_bib13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.abb.2012.03.001","article-title":"Antibody-cytokine fusion proteins","volume":"526","author":"Kontermann","year":"2012","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.esmoop.2026.107697_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40259-013-0069-7","article-title":"Antibody-cytokine fusion proteins for cancer immunotherapy: An update on recent developments","volume":"28","author":"M\u00fcller","year":"2014","journal-title":"BioDrugs"},{"key":"10.1016\/j.esmoop.2026.107697_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1277306","article-title":"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines","volume":"6","author":"Klein","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.esmoop.2026.107697_bib16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nbt0518-378","article-title":"Cytokine resurrection: engineered IL-2 ramps up immuno-oncology responses","volume":"36","author":"Garber","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.esmoop.2026.107697_bib17","doi-asserted-by":"crossref","first-page":"24737","DOI":"10.18632\/oncotarget.25343","article-title":"89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding","volume":"9","author":"van Brummelen","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2026.107697_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012885","article-title":"Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors","volume":"14","author":"Melero","year":"2026","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.esmoop.2026.107697_bib19","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/sim.3230","article-title":"Critical aspects of the Bayesian approach to phase I cancer trials","volume":"27","author":"Neuenschwander","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.esmoop.2026.107697_bib20","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1158\/1078-0432.CCR-17-2953","article-title":"Prediction of the optimal dosing regimen using a mathematical model of tumor uptake for immunocytokine-based cancer immunotherapy","volume":"24","author":"Ribba","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.107697_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.107697_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.esmoop.2026.107697_bib23","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/1078-0432.CCR-23-2658","article-title":"Obinutuzumab pretreatment as a novel approach to mitigate formation of anti-drug antibodies against cergutuzumab amunaleukin in patients with solid tumors","volume":"30","author":"Peters","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.107697_bib24","author":"Clinigen"},{"key":"10.1016\/j.esmoop.2026.107697_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (aldesleukin)\u2014expert consensus on best management practices\u20142014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.esmoop.2026.107697_bib26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/cancers9050050","article-title":"Immunotherapy for colorectal cancer","volume":"9","author":"Boland","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.esmoop.2026.107697_bib27","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107697_bib28","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1158\/1078-0432.CCR-25-2440","article-title":"Cergutuzumab amunaleukin in combination with atezolizumab in patients with carcinoembryonic antigen-positive advanced\/metastatic solid tumors","volume":"32","author":"Melero","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.107697_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105374","article-title":"Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and\/or metastatic cervical squamous cell carcinoma","volume":"109","author":"Verlingue","year":"2024","journal-title":"EBioMedicine"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292601639X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292601639X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:12:55Z","timestamp":1780290775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292601639X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S205970292601639X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107697","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and\/or metastatic solid tumors","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107697"}}